Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190378 | 1.00 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL8776005 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL933037 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL190003 | 0.79 | DPYD (0.62) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL6374582 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL15798473 | 0.79 | DPYD (0.62) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL6374591 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL65892 | 0.79 | DPYD (0.62) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL12903446 | 0.79 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA | |
| SCHEMBL190328 | 0.76 | DPYD (0.59) | DPYDMAPTALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2020-03-19 | — | — | US | disclosed |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | EMORY UNIVERSITY | 2003-09-18 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003053360-A2 | TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION | PHARMASSETT LTD. (BB) | 2003-07-03 | — | — | WO | disclosed |
| EP-0649840-B1 | Bis(hydroxymethyl)cyclopropylmethyl pyrimidine derivatives, their preparation and their use as anti-viral agents | AJINOMOTO KK (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-5496824-A | ZOSTER VIRUS WITH PYRIMIDINEDIONE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0649840-A1 | Bis(hydroxymethyl)cyclopropylmethyl pyrimidine derivatives, their preparation and their use as anti-viral agents | Ajinomoto Co., Inc. (JP) | 1995-04-26 | — | — | EP | disclosed |
| US-4668778-A | Nucleoside 5'-alkyl- or alkenylphosphate | YAMASA SHOYU KABUSHIKI KAISHA (JP) | 1987-05-26 | — | — | US | disclosed |
| EP-0097376-B1 | NUCLEOSIDE 5'-ALKYL- OR ALKENYLPHOSPHATE | Yamasa Shoyu Kabushiki Kaisha (JP) | 1986-09-17 | — | — | EP | disclosed |
| EP-0097376-A1 | Nucleoside 5'-alkyl- or alkenylphosphate | Yamasa Shoyu Kabushiki Kaisha (JP) | 1984-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | DPYD 35/4885MAPT 4192/4885ALDH1A1 2152/4885 |
| US-20030176392-A1 | Administering 5-substituted uracil-nucleosides or its pharmaceutically acceptable salt or prodrug for therapy of infected with Epstein-Barr virus or Kaposi's sarcoma-associated herpes (\"KHSV\") | UMPS, UNG, TYMP | DPYD 14/4885MAPT 2314/4885ALDH1A1 1351/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | DPYD 165/4885MAPT 4330/4885ALDH1A1 2723/4885 |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TPMT, ADAR | DPYD 36/4885MAPT 4237/4885ALDH1A1 1877/4885 |
| US-20200085820-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | DPYD 53/4885MAPT 4104/4885ALDH1A1 2891/4885 |
| US-10682350-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | DPYD 53/4885MAPT 4104/4885ALDH1A1 2891/4885 |
| US-10709703-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | DPYD 53/4885MAPT 4104/4885ALDH1A1 2891/4885 |
| US-10314840-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | DPYD 53/4885MAPT 4104/4885ALDH1A1 2891/4885 |
| US-10369148-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | DPYD 53/4885MAPT 4104/4885ALDH1A1 2891/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | DPYD 53/4885MAPT 4104/4885ALDH1A1 2891/4885 |
| US-20190255047-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | DPYD 53/4885MAPT 4104/4885ALDH1A1 2891/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | DPYD 53/4885MAPT 4104/4885ALDH1A1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.